Q-omics provides the consensus-scored HOXD8 profile across patient tissues and cancer cell-line models. HOXD8 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HOXD8 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, HOXD8 RNA expression shows 18,259 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where HOXD8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HOXD8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HOXD8 survival associations across molecular data types. HOXD8 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HOXD8 RNA expression–survival associations across cancer types. High HOXD8 expression shows unfavorable associations in KIRP, ACC, UVM, LIHC and LGG, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HOXD8 RNA expression.
This table summarizes HOXD8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HOXD8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HOXD8 shows lower tumor expression in KIRC, KIRP, KICH and COAD and higher tumor expression in HNSC and LIHC. The HNSC box plot shows higher HOXD8 RNA expression in tumor versus normal tissue (log2 FC = +2.136, t-test p < 0.001).
This table shows molecular features associated with HOXD8 in patient tissues and cancer cell lines. In patient samples, HOXD8 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, HOXD8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
